Beat · Healthcare / Biotech
Healthcare / Biotech: the podcasts, blogs, shows and changelogs worth following
Drug development, health-system economics, and the regulator that gates both. These are the public sources Briefwire reads to cover it — the podcasts, blogs, shows and changelogs — each fetched and checked before it is listed, and each with a note on what it is good for.
Podcasts, blogs, shows and changelogs.
trial · approval · reimbursement · funding
19 September 2026. Every source is English-language and public: nothing behind a paywall or a login is read.
Podcasts
Where operators and investors reason out loud at length. The receipt for a line from one of these is a timestamp.
- Business of Biotech
Biotech-executive interviews on financing and manufacturing; ships episode transcripts.
- A Health Podyssey
Health Affairs authors explaining their own study's policy consequences; ships transcripts, so the health-policy evidence layer is extractable.
- Relentless Health Value
Stacey Richter pressing payer, employer and provider executives on where the money actually goes; transcripts published for 400 episodes.
- Healthcare Unfiltered (Chadi Nabhan)
A practising oncologist interviewing pharma and oncology leaders with unusual candour on pricing and evidence; transcripts included.
- Medsider
Medtech founders and CEOs on FDA pathways, reimbursement and raising capital; transcripts make 250 device-exec interviews searchable.
- CareTalk
Two health-industry operators arguing about payer and provider strategy weekly, with named guests and transcripts.
- The Readout Loud
STAT's weekly biotech show; reporters explain what a readout means commercially.
- Raising Health
a16z Bio+Health's show on healthcare business models and reimbursement.
- The Heart of Healthcare
Digital-health CEO interviews on payer contracts and go-to-market.
- The Long Run
Luke Timmerman's biotech-leader interviews; deep on capital markets for drug developers.
- Claims Denied (Hospitalogy)
Health-system finance show from the Hospitalogy team; payer-provider economics.
A clinical analyst on evidence quality in medical AI; the counterweight to vendor claims.
- Lifers (Christina Farr)
A former CNBC health-tech reporter turned investor interviewing digital-health operators; strong on why companies actually failed.
- Biotech 2050
Biotech CEO and founder interviews on platform strategy and financing; complements the Long Run's capital-markets angle already held.
- Tradeoffs
Health-policy reporting built on interviews with the researchers and administrators making coverage decisions; rigorous on Medicaid.
Blogs and newsletters
Company engineering blogs, analyst newsletters and practitioner posts. The receipt is the paragraph.
Best-in-class biotech and health-policy reporting; the default industry citation.
Drug-development and pharma-business coverage; trial results and licensing deals.
Digital-health and payer-provider coverage; strong on funding and partnership news.
Provider and payer strategy, M&A and regulation; core US health-system tracking.
Non-profit health-policy journalism; the reference for coverage and cost analysis.
Blake Madden's health-system financial analysis; margin and consolidation detail for consultants.
Long-running commentary from health-policy practitioners and digital-health founders.
Approvals, recalls and enforcement direct from the regulator — the primary dating source.
Pharma R&D and manufacturing trade coverage; platform-technology adoption and CDMO capacity.
Structured recall events; the way to track a competitor's quality failures on the record.
CDER's own stream of approvals, labeling changes and guidance — narrower and faster than the press-release feed already in the library.
UK medicines and device regulator's announcements — approvals, safety alerts and enforcement; the news stream, not the corporate-report stream.
Payment rules and coverage rulemaking from the largest US payer; reimbursement changes appear here before any trade write-up.
Outbreak declarations, MMWR-linked announcements and agency guidance; cdc.gov itself serves no feed, this syndication API is the one it links.
Clinical-AI and EHR-evaluation preprints; the evidence layer under digital-health vendor performance claims.
Open-access clinical research with full text available — unlike the paywalled majors, the article itself is ingestible, not just the abstract.
Epic's own analyses across its de-identified EHR footprint; the largest US clinical dataset publishing findings under its own name.
The health-system-owned data collective publishing its own real-world-evidence studies; useful as the counterweight to pharma-funded RWE.
Consumer-genomics research and policy posts first-party; note the feed now lives on the .org domain after a redirect, not .com.
Trial readouts, approvals and litigation statements from the largest healthcare company, in its own words and dated.
- Drug Channels (Adam Fein)
The single best source on PBM economics, gross-to-net and pharmacy consolidation; one named economist with his reputation on every post.
An Atlas Venture partner writing candidly on biotech financing, startup failure rates and venture returns under his own byline.
Long-form essays on biotechnology's technical frontier by named working scientists; low cadence, so watch it against the six-month rule.
Bioprocessing, tools and genomics trade coverage; the reliable read on instrument and CDMO capacity moves.
Clinical-trial outcomes and pipeline decisions with consistent, dated reporting.
Device makers, FDA clearances and medtech competitive moves; dates the approval race.
Big-pharma pipeline and regulatory announcements first-party; the deepest archive of any pharma feed tested, and all of it dated.
Healthcare business models explained without consultant hedging; the reference read on why a digital-health company actually makes money.
Pharma commercial and R&D-organisation reporting — leadership moves, launch strategy and the people side the pipeline trades skip.
YouTube shows
Interviews, conference talks and explainers, read from their published captions.
Author interviews on major studies; the clinical-evidence layer behind market claims.
Digital-health funding roundtables with founders and investors on the record.
Journalists interviewing pharma executives and FDA figures; quotable and dated.
The dominant life-sciences cloud vendor running serial interviews on clinical-data architecture and trial-outsourcing economics.
AI-native drug discovery explained by the company making the claim, including quarterly earnings calls posted in full.
Release feeds and changelogs
What actually shipped, from the projects’ own release notes — the check on what was said elsewhere.
Just the Healthcare / Biotech changelogs and release feeds →
Open-source FHIR-native healthcare developer platform; releases date what digital-health builders can assemble without an EHR vendor.
The most-deployed open-source EHR; release notes name the certification and billing requirements small practices must meet.
The NVIDIA/King's-backed medical-imaging AI framework behind many cleared radiology products; releases date the underlying capability.
Synthetic patient-record generator used across payer and vendor testing; its disease modules encode how care pathways are being modelled.
The de-facto standard variant caller from the Broad; a change here propagates through clinical-genomics pipelines industry-wide.
Curated bioinformatics pipelines used by most sequencing cores; tracks the reproducibility standard biotech R&D is converging on.
The cancer-genomics portal most translational groups run; release notes date the data-model changes downstream pipelines have to follow.
The reference Java FHIR implementation most interoperability stacks build on; its releases track how the standard is actually adopted.
What Briefwire does with them
- 01Reads
Every source above is fetched through the day. Spoken sources are read from their published transcript or captions; written ones from the post itself.
- 02Extracts and matches
Discrete claims are pulled out, typed — a product move, a data point, a prediction, an opinion — and matched against the same claim from other publishers.
- 03Ranks and sends
The 12 lines that rank highest go out as a brief, daily or weekly at the hour you choose. A claim several independent sources made ranks higher; that counts agreement, not accuracy, and every line links to where it was said.
More on the method: how a line earns its place, what industry intelligence is, and how this differs from page monitors, podcast summarisers, industry newsletters, and the other tools you may already run.
Run one of the sources above, or think one is missing? How sources are attributed, and how to reach us.
The other industries Briefwire reads
- AI ToolingModel labs, inference platforms, and the release feeds that date every capability claim.
- Dev Tools & InfraCloud platforms, developer infrastructure, and the changelogs that date every shipped feature.
- B2B SaaS & GTMSaaS operating benchmarks, pricing and go-to-market, from operators and the tools they run on.
- E-commerce / DTCRetail and DTC economics: platform changes, channel costs, and merchant-side reality.
- Fintech & PaymentsPayments infrastructure, banking strategy, and the regulators who reset both.
- Crypto & StablecoinsDigital-asset markets, stablecoin issuance, and the protocol releases underneath them.
- CybersecurityThreat intelligence, breach reporting, and the advisories that drive enterprise security spend.
- Climate & EnergyEnergy-transition project economics, utility strategy, and climate-tech capital flows.
- Semiconductors / Hardware / RoboticsSilicon supply chains, independent hardware measurement, and the robotics companies buying it all.
- Legal & RegTechLegal technology adoption, law-firm buying, and the enforcement actions that create compliance demand.
- HR & Future of WorkHiring tools, workforce data, and the employment rules that reset employer obligations.
- Insurance & InsurtechCarrier strategy, reinsurance pricing, and the distribution and core-system modernisation underneath.
- Real Estate & PropTechCommercial real-estate capital markets, mortgage technology, and construction-site digitisation.
- Logistics & Supply ChainFreight rates, capacity, forwarder margin, and the regulators who move all three.
- Manufacturing & IndustrialAutomation purchasing, plant capex, and the robotics platforms industrial buyers standardise on.
- Media & Creator EconomyPublisher revenue models, programmatic advertising, and the platform rule changes both depend on.
- GamingStudio economics, platform policy, engine migration, and the discovery data that drives publishing.
Healthcare / Biotech in 12 lines a brief, each with a receipt.
14 days of Desk, every seat, card on file — cancel before day 14 and it is never charged. Or take three lines free by email every Monday, no account.